Recruitment of FBXO22 for targeted degradation of NSD2.

Autor: Nie DY; Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada.; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada., Tabor JR; Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Li J; University of Florida Health Cancer Center, Gainesville, FL, USA.; Department of Pharmacology, Physiology, and Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA., Kutera M; Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada.; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada., St-Germain J; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada., Hanley RP; Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.; C4 Therapeutics, Watertown, MA, USA., Wolf E; Department of Chemistry, York University, Toronto, Ontario, Canada., Paulakonis E; Department of Pharmacology, University of North Carolina, Chapel Hill, NC, USA., Kenney TMG; Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada.; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada., Duan S; Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada.; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada., Shrestha S; Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada.; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada., Owens DDG; Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada.; Amphista Therapeutics, Cambridge, UK., Maitland MER; Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada., Pon A; Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada., Szewczyk M; Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada., Lamberto AJ; University of Florida Health Cancer Center, Gainesville, FL, USA., Menes M; University of Florida Health Cancer Center, Gainesville, FL, USA., Li F; Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada., Penn LZ; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada., Barsyte-Lovejoy D; Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada.; Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario, Canada., Brown NG; Department of Pharmacology, University of North Carolina, Chapel Hill, NC, USA.; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Barsotti AM; Deerfield Discovery and Development, Deerfield Management, New York, NY, USA., Stamford AW; Deerfield Discovery and Development, Deerfield Management, New York, NY, USA., Collins JL; Office of the Vice Chancellor for Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Wilson DJ; Department of Chemistry, York University, Toronto, Ontario, Canada., Raught B; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada., Licht JD; University of Florida Health Cancer Center, Gainesville, FL, USA., James LI; Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. ingerman@email.unc.edu.; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. ingerman@email.unc.edu., Arrowsmith CH; Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada. cheryl.arrowsmith@uhn.ca.; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. cheryl.arrowsmith@uhn.ca.; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada. cheryl.arrowsmith@uhn.ca.

Publikováno v: Nature chemical biology [Nat Chem Biol] 2024 Dec; Vol. 20 (12), pp. 1597-1607. Date of Electronic Publication: 2024 Jul 04.

Structure-function analysis of the SHOC2-MRAS-PP1C holophosphatase complex.

Autor: Kwon JJ; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, Massachusetts, USA., Hajian B; Center for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Bian Y; Center for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Young LC; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA., Amor AJ; Center for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Fuller JR; Helix Biostructures, Indianapolis, IN, USA., Fraley CV; Center for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Sykes AM; Harvard Medical School, Boston, Massachusetts, USA.; Center for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA., So J; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, Massachusetts, USA., Pan J; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, Massachusetts, USA., Baker L; Center for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Lee SJ; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, Massachusetts, USA., Wheeler DB; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Mayhew DL; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, Massachusetts, USA., Persky NS; Genetic Perturbation Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Yang X; Genetic Perturbation Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Root DE; Genetic Perturbation Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Barsotti AM; Deerfield Discovery and Development, Deerfield Management, New York, NY, USA., Stamford AW; Deerfield Discovery and Development, Deerfield Management, New York, NY, USA., Perry CK; Center for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Burgin A; Center for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA., McCormick F; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.; NCI RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, USA., Lemke CT; Center for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA. clemke@broadinstitute.org., Hahn WC; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA. william_hahn@dfci.harvard.edu.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. william_hahn@dfci.harvard.edu.; Harvard Medical School, Boston, Massachusetts, USA. william_hahn@dfci.harvard.edu.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. william_hahn@dfci.harvard.edu., Aguirre AJ; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA. andrew_aguirre@dfci.harvard.edu.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. andrew_aguirre@dfci.harvard.edu.; Harvard Medical School, Boston, Massachusetts, USA. andrew_aguirre@dfci.harvard.edu.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. andrew_aguirre@dfci.harvard.edu.

Publikováno v: Nature [Nature] 2022 Sep; Vol. 609 (7926), pp. 408-415. Date of Electronic Publication: 2022 Jul 13.

p53 Represses the Mevalonate Pathway to Mediate Tumor Suppression.

Autor: Moon SH; Department of Biological Sciences, Columbia University, New York, NY 10027, USA., Huang CH; Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Cell and Developmental Biology Program, Weill Graduate School of Medical Sciences, Cornell University, New York, NY 10065, USA; Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA., Houlihan SL; Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA., Regunath K; Department of Biological Sciences, Columbia University, New York, NY 10027, USA., Freed-Pastor WA; Department of Biological Sciences, Columbia University, New York, NY 10027, USA., Morris JP 4th; Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA., Tschaharganeh DF; Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA., Kastenhuber ER; Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Louis V. Gerstner Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA., Barsotti AM; Department of Biological Sciences, Columbia University, New York, NY 10027, USA., Culp-Hill R; Department of Biochemistry and Molecular Genetics, University of Colorado Denver - Anschutz Medical Campus, Aurora, CO 80045, USA., Xue W; Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA., Ho YJ; Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA., Baslan T; Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA., Li X; Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Cell and Developmental Biology Program, Weill Graduate School of Medical Sciences, Cornell University, New York, NY 10065, USA., Mayle A; Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA., de Stanchina E; Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA., Zender L; Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA., Tong DR; Department of Biological Sciences, Columbia University, New York, NY 10027, USA., D'Alessandro A; Department of Biochemistry and Molecular Genetics, University of Colorado Denver - Anschutz Medical Campus, Aurora, CO 80045, USA., Lowe SW; Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: lowes@mskcc.org., Prives C; Department of Biological Sciences, Columbia University, New York, NY 10027, USA. Electronic address: clp3@columbia.edu.

Publikováno v: Cell [Cell] 2019 Jan 24; Vol. 176 (3), pp. 564-580.e19. Date of Electronic Publication: 2018 Dec 20.

Reciprocal regulation of amino acid import and epigenetic state through Lat1 and EZH2.

Autor: Dann SG; Pfizer Oncology Research Unit, San Diego, CA, USA stephen.dann@pfizer.com., Ryskin M; Pfizer Oncology Research Unit, Pearl River, NY, USA., Barsotti AM; Pfizer Oncology Research Unit, Pearl River, NY, USA., Golas J; Pfizer Oncology Research Unit, Pearl River, NY, USA., Shi C; Pfizer Oncology Research Unit, Pearl River, NY, USA., Miranda M; Pfizer Oncology Research Unit, Pearl River, NY, USA., Hosselet C; Pfizer Oncology Research Unit, Pearl River, NY, USA., Lemon L; Pfizer Oncology Research Unit, Pearl River, NY, USA., Lucas J; Pfizer Oncology Research Unit, Pearl River, NY, USA., Karnoub M; Celgene, Summit, NJ, USA., Wang F; Pfizer Oncology Research Unit, Pearl River, NY, USA., Myers JS; Pfizer Oncology Research Unit, Pearl River, NY, USA., Garza SJ; Pfizer Oncology Research Unit, San Diego, CA, USA., Follettie MT; Pfizer Oncology Research Unit, Pearl River, NY, USA., Geles KG; Pfizer Oncology Research Unit, Pearl River, NY, USA., Klippel A; Celgene, Summit, NJ, USA., Rollins RA; Pfizer Oncology Research Unit, Pearl River, NY, USA., Fantin VR; Pfizer Oncology Research Unit, San Diego, CA, USA.

Publikováno v: The EMBO journal [EMBO J] 2015 Jul 02; Vol. 34 (13), pp. 1773-85. Date of Electronic Publication: 2015 May 15.

Epigenetic reprogramming by tumor-derived EZH2 gain-of-function mutations promotes aggressive 3D cell morphologies and enhances melanoma tumor growth.

Autor: Barsotti AM; Oncology Research Unit, Pfizer Worldwide Research and Development, Pearl River, NY 10965, USA., Ryskin M; Oncology Research Unit, Pfizer Worldwide Research and Development, Pearl River, NY 10965, USA., Zhong W; Oncology Research Unit, Pfizer Worldwide Research and Development, Pearl River, NY 10965, USA., Zhang WG; Oncology Research Unit, Pfizer Worldwide Research and Development, Pearl River, NY 10965, USA., Giannakou A; Oncology Research Unit, Pfizer Worldwide Research and Development, Pearl River, NY 10965, USA., Loreth C; Oncology Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA 02140, USA., Diesl V; Oncology Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA 02140, USA., Follettie M; Oncology Research Unit, Pfizer Worldwide Research and Development, Pearl River, NY 10965, USA.; Oncology Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA 02140, USA., Golas J; Oncology Research Unit, Pfizer Worldwide Research and Development, Pearl River, NY 10965, USA., Lee M; Drug Safety Research and Development, Pfizer Worldwide Research and Development, San Diego, CA 92121, USA., Nichols T; Drug Safety Research and Development, Pfizer Worldwide Research and Development, San Diego, CA 92121, USA., Fan C; Oncology Research Unit, Pfizer Worldwide Research and Development, San Diego, CA 92121, USA., Li G; Oncology Research Unit, Pfizer Worldwide Research and Development, San Diego, CA 92121, USA., Dann S; Oncology Research Unit, Pfizer Worldwide Research and Development, San Diego, CA 92121, USA., Fantin VR; Oncology Research Unit, Pfizer Worldwide Research and Development, San Diego, CA 92121, USA., Arndt K; Oncology Research Unit, Pfizer Worldwide Research and Development, Pearl River, NY 10965, USA., Verhelle D; Oncology Research Unit, Pfizer Worldwide Research and Development, San Diego, CA 92121, USA., Rollins RA; Oncology Research Unit, Pfizer Worldwide Research and Development, Pearl River, NY 10965, USA.

Publikováno v: Oncotarget [Oncotarget] 2015 Feb 20; Vol. 6 (5), pp. 2928-38.